Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FogPharma
Biotech
Tumor-focused Parabilis raises $305M to 'upend status quo'
The biotech will harness the cash to advance FOG-001, recently named zolucatetide, towards a pivotal phase 3 trial in desmoid tumors.
Darren Incorvaia
Jan 8, 2026 7:00am
FogPharma clears $145M series E thanks to Borisy, ex-J&J CEO
Mar 1, 2024 9:55am
BMS CEO set to leave after 8-year run—Chutes & Ladders
Apr 28, 2023 9:30am
Ex-J&J research chief lands at FogPharma—Chutes & Ladders
Mar 31, 2023 9:30am
Former J&J R&D chief Mathai Mammen lands at FogPharma
Mar 30, 2023 6:00am
FogPharma hauls in $178M series D
Nov 21, 2022 4:33pm
